TrialLancet (London, England)2016

Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer's disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial.

Serge Gauthier et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.